Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma
NCT04954794Phase 2Completed
- Sponsor
- Fudan University
- Start
- Jul 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by Fudan University. Started Jul 2021; status: completed.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04954794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954794.